Notably, although cDC2s and monocyte-derived DCs comprise most of the myeloid APCs in the TME (5), a recent study showed that tumor-specific T cells were primarily activated in the TME by cDC1s (75), which functioned simultaneously to support both CD8+ and CD4+ T cell priming (66). The gene discussed is CD8A; the disease is neoplasm.